Compare Nano Dimension Ltd - ADR (NNDM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Viatris Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.48 (market cap $322.08M), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 61.4× Nano Dimension Ltd - ADR's market cap, and Viatris Inc pays a 2.83% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| NNDM | VTRS | |
|---|---|---|
Market Cap | $322.08M | $19.79B |
Sector | Technology | Health |
52-Week High | $2.14 | $17.39 |
52-Week Low | $1.21 | $8.74 |
Enterprise Value | -$87.26M | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.49, down 3.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $102.44 million in 2025 but a net loss of $293.30 million, reflecting a negative net income margin of 286.72%. Recent news highlights board changes, cost-saving initiatives, and a proposed business combination with Infinite Epigenetics.
The outlook remains challenging due to persistent losses and negative cash flow, though cost reductions and strategic moves aim to stabilize. Key risks include execution of the turnaround plan and shareholder disputes. Analyst sentiment is mixed, with the stock trading below book value, indicating potential value if operations improve.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
